SEC Filings

Form Description Filing date View
4

Statement of changes in beneficial ownership of securities

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
SC 13G/A

An amendment to the SC 13G filing

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.INS - XBRL INSTANCE DOCUMENT
4

Statement of changes in beneficial ownership of securities

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline